Physician profile
Alexander Postalian
NPI 1821436635
$39,089.81
in general payments reported to CMS, 2019-2025
59 companies · $8,131 in 2025
The $8,131 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $4,543 · 2020: $5,452 · 2021: $3,880 · 2022: $5,126 · 2023: $3,411 · 2024: $8,547 · 2025: $8,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $8,081 · Travel and Lodging: $1,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,508.57 |
| Consulting Fee | $8,081.25 |
| Travel and Lodging | $1,499.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $8,602.71 | 2020-2025 | |
| Abbott Laboratories | $5,239.50 | 2019-2025 | Triclip, Xience Skypoint, Dragonfly Opstar |
| Medtronic, INC. | $3,793.46 | 2021-2025 | Venaseal, Corevalve Evolut R, Endurant Iis |
| Medtronic Vascular, INC. | $3,576.95 | 2019-2020 | |
| Boston Scientific Corporation | $1,913.52 | 2019-2025 | Ekosonic, Eluvia, General - Therapies |
| Argon Medical Devices, INC. | $1,650.00 | 2022-2024 | Clot Mgmt, Cleaner |
| Amgen INC. | $1,353.65 | 2019-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $1,117.07 | 2019-2025 | Pascal |
| Janssen Pharmaceuticals, INC | $1,072.24 | 2020-2024 | Xarelto |
| Endologix LLC | $1,070.89 | 2021 | |
| Bard Peripheral Vascular, INC. | $929.66 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $872.60 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $736.24 | 2022-2025 | Wegovy, Ozempic, Fiasp |
| Pfizer INC. | $603.17 | 2019-2025 | |
| Shockwave Medical, INC | $513.15 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $403.04 | 2021-2024 | Optimizer, Optimizer |
| Actelion Pharmaceuticals US, INC. | $392.41 | 2022-2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $351.81 | 2021-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $330.54 | 2020-2025 | Lifevest |
| Amarin Pharma, INC. | $314.32 | 2020-2023 | |
| Cardiva Medical, INC. | $302.57 | 2022-2023 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| W. L. Gore & Associates, INC. | $297.65 | 2023-2024 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Inspiremd LTD | $263.34 | 2025 | Cguard Prime Carotid Stent System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.93 | 2021-2025 | Jardiance |
| Esperion Therapeutics, INC. | $220.20 | 2021-2025 | Nexletol |
| Abiomed | $212.12 | 2022-2025 | |
| Inari Medical, INC. | $200.08 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $188.78 | 2019-2025 | Wainua |
| Teleflex LLC | $179.74 | 2023-2024 | Manta |
| Sanofi-Aventis U.S. LLC | $165.90 | 2021-2024 | |
| Philips North America LLC | $164.72 | 2022-2024 | (Bh4) Igt Devices Undivided |
| Bayer Healthcare Pharmaceuticals INC. | $158.29 | 2022-2025 | |
| Penumbra, INC. | $157.91 | 2020-2024 | Indigo System |
| Irhythm Technologies, INC. | $156.45 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Astellas Pharma US INC | $149.13 | 2019-2020 | |
| Endotronix, INC. | $146.57 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Lexicon Pharmaceuticals, INC. | $137.60 | 2023-2024 | Inpefa |
| Alnylam Pharmaceuticals INC. | $137.36 | 2024-2025 | Onpattro, Amvuttra |
| Kowa Pharmaceuticals America, INC. | $127.13 | 2021-2023 | Livalo |
| Zoll Circulation INC | $83.84 | 2021 | |
| Cardiovascular Systems INC. | $83.74 | 2019-2020 | |
| Bridgebio Pharma, INC. | $59.27 | 2025 | Attruby |
| Avinger INC. | $56.78 | 2020-2021 | |
| Vifor Pharma, INC. | $49.90 | 2021 | |
| Chiesi USA, INC. | $49.76 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $39.53 | 2023 | Arcalyst |
| Heartflow, INC. | $29.24 | 2019-2024 | |
| Bolton Medical INC | $25.64 | 2023 | Treo Abdominal Stent-Graft System |
| Thrombolex, INC. | $22.48 | 2023 | |
| Portola Pharmaceuticals, LLC | $21.42 | 2020 | |
| Saranas, INC. | $20.64 | 2023 | |
| Genzyme Corporation | $20.27 | 2022 | |
| Inspire Medical Systems, INC. | $19.34 | 2024 | Inspire |
| Bracco Diagnostics INC. | $17.33 | 2022 | |
| Medicomp INC | $16.74 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $14.15 | 2024 | Arcalyst |
| Tactile Systems Technology INC | $12.56 | 2021 | |
| Medicure Pharma INC. | $11.78 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$149.16 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Postalian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.